Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Countries citing papers authored by D. R. Abernethy
Since
Specialization
Citations
This map shows the geographic impact of D. R. Abernethy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. R. Abernethy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. R. Abernethy more than expected).
This network shows the impact of papers produced by D. R. Abernethy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. R. Abernethy. The network helps show where D. R. Abernethy may publish in the future.
Co-authorship network of co-authors of D. R. Abernethy
This figure shows the co-authorship network connecting the top 25 collaborators of D. R. Abernethy.
A scholar is included among the top collaborators of D. R. Abernethy based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with D. R. Abernethy. D. R. Abernethy is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Donahue, Stephen, Jerry M. Collins, D. A. Flockhart, D. R. Abernethy, & Carol Braun Trapnell. (1997). Thalidomide pharmacokinetics do not change with chronic administration. Clinical Pharmacology & Therapeutics. 61(2).3 indexed citations
Abernethy, D. R., et al.. (1985). Verapamil dynamics and disposition in obese hypertensives. Federation Proceedings. 44(5).4 indexed citations
15.
Divoll, Marcia, D. R. Abernethy, & David J. Greenblatt. (1982). Cimetidine impairs drug oxidizing capacity in the elderly. Clinical Pharmacology & Therapeutics. 31(2).1 indexed citations
16.
Abernethy, D. R., David J. Greenblatt, & Marcia Divoll. (1982). Differential effects of cimetidine on drug oxidation vs conjugation: Potential mode of therapy for acetaminophen hepatotoxicity. Clinical Pharmacology & Therapeutics. 31(2).4 indexed citations
17.
Abernethy, D. R., David J. Greenblatt, Marcia Divoll, & R Arendt. (1982). Impairment of diazepam clearance with low-dose oral contraceptive steroid therapy. Clinical Pharmacology & Therapeutics. 31(2). 198–199.6 indexed citations
18.
Abernethy, D. R., David J. Greenblatt, Marcia Divoll, & Richard I. Shader. (1982). Drug glucuronidation in obesity. Clinical research. 30(3).1 indexed citations
19.
Abernethy, D. R. & David J. Greenblatt. (1981). Metabolite-parent drug interaction study: Desmethyldiazepam effect on diazepam kinetics. Clinical Pharmacology & Therapeutics. 29(2). 230–231.2 indexed citations
20.
Abernethy, D. R., Marcia Divoll, Barbara Ameer, & David J. Greenblatt. (1981). Acetaminophen kinetics in obesity. Clinical Pharmacology & Therapeutics. 29(2).2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.